智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX11获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use，"CHMP")积极审评意见，推荐批准HLX11的上市许可申请。CHMP 的审评意见将会被递交至欧盟委员会(European Commission，"EC")， EC将参考该意见并在未来2-3个月 做出最终审查决定。倘若获得EC批准，HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA) 国家冰岛、列支敦士登和挪威生效。 此次CHMP的积极意见主要是基于HLX11对比参照药Perjeta®(帕妥珠单抗)产生的数据，包括分析相似 性研究、药代动力学相似性研究及临床比对研究。这些数据都证明了HLX11与参照药Perjeta®在质量、 安全性和有效性方面的高度相似。2025年6月，本集团收到比利时联邦药品和保健产品管理局 (Federal Agency For Medicines And Health Products)颁发的两项GMP证书，说明HLX11相关生产线已符合欧盟 GMP标准。 HLX11是本公司自主研发的帕妥 ...

复宏汉霖(02696)发布公告，近日，HLX22(重组人源化抗HER2单克隆抗体注射液)(HLX22)联合注射用 HLX87(靶向HER2抗体偶联药物)(HLX87)一线治疗HER2阳性复发或转移性乳腺癌(BC)患者的2/3期临床 研究于中国境内(不包括中国港澳台地区，下同)完成首例患者给药。 本研究是一项评估HLX22联合HLX87一线治疗HER2阳性复发或转移性乳腺癌患者的开放、随机、多中 心的2/3期临床研究。研究包括两个阶段，第一阶段是一项开放、多中心、随机、平行对照的2期临床研 究，合格受试者将按照2:2:1:1的比例随机分配接受HLX22联合HLX87、帕妥珠单抗联合HLX87、帕妥珠 单抗联合德曲妥珠单抗或帕妥珠单抗联合曲妥珠单抗及多西他赛治疗。第一阶段的主要终点是独立影像 评估委员会(BICR)评估的客观缓解率(ORR)及无进展生存期(PFS)。第二阶段是一项开放、多中心、随 机、平行对照的3期临床研究，合格受试者将按照1:1的比例随机分配接受HLX22联合HLX87或帕妥珠单 抗联合曲妥珠单抗及多西他赛治疗。第二阶段的主要终点是BICR评估的PFS。本次研究的主要目的是 评估HLX22联合H ...

本研究是一项评估HLX22联合HLX87一线治疗HER2阳性复发或转移性乳腺癌患者的开放、随机、多中 心的2/3期临床研究。研究包括两个阶段，第一阶段是一项开放、多中心、随机、平行对照的2期临床研 究，合格受试者将按照 2:2:1:1的比例随机分配接受HLX22联合HLX87、帕妥珠单抗联合HLX87、帕妥 珠单抗联合德曲妥珠单抗或帕妥珠单抗联合曲妥珠单抗及多西他赛治疗。第一阶段的主要终点是独立影 像评估委员会(BICR)评估的客观缓解率(ORR)及无进展生存期(PFS)。第二阶段是一项开放、多中心、 随机、平行对照的3期临床研究，合格受试者将按照1:1的比例随机分配接受HLX22联合HLX87或帕妥珠 单抗联合曲妥珠单抗及多西他赛治疗。第二阶段的主要终点是BICR评估的PFS。本次研究的主要目的 是评估HLX22联合HLX87一线治疗HER2阳性复发或转移性乳腺癌的临床疗效，次要目的包括评估 HLX22联合HLX87的安全性、耐受性、药代动力学(PK)特征及免疫原性，探索潜在的预测性或耐药性 生物标志物。 智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX22(重组人源化抗HER2单克隆抗体注射 ...

Investment Rating - The report assigns an investment rating of "Outperform the Market" for the pharmaceutical sector, indicating a relative performance better than the benchmark index [8]. Core Insights - The pharmaceutical sector has shown resilience, with the SW Pharmaceutical Bio Index declining only 0.14% compared to the Shanghai and Shenzhen 300 Index's decline of 0.28% during the week of December 15-21 [2]. - The report highlights significant developments in AI healthcare, particularly with the launch of Ant Group's upgraded AI health app "Antifufu," which aims to enhance health management for users [2]. - Insilico Medicine's IPO is anticipated to drive innovation in drug development, with a focus on its AI-driven platform Pharma.AI and promising clinical results for its lead product Rentosertib [2]. - The approval of the Enhertu and trastuzumab combination therapy for HER2-positive breast cancer is expected to redefine first-line treatment standards in this area [2]. - The report emphasizes the potential of Chinese innovative drugs in international markets and suggests continued monitoring of key sectors such as ADCs, bispecific antibodies, and weight-loss drugs [2]. Summary by Sections Industry Performance - The pharmaceutical sector's weekly trading volume was 389.82 billion yuan, showing a slight decline compared to previous weeks, indicating a need for recovery in market sentiment [2]. AI Healthcare Developments - The "Antifufu" app connects users with 300,000 real doctors for online consultations and has over 15 million monthly active users, with 55% from lower-tier cities, showcasing the app's broad reach [2]. IPO and Drug Development - Insilico Medicine's IPO is set for December 30, with a total fundraising target of 2.277 billion HKD, primarily for clinical research of its drug pipeline [2][5]. Treatment Innovations - The Enhertu and trastuzumab combination therapy has shown a significant improvement in progression-free survival rates, marking a major advancement in treatment options for HER2-positive breast cancer [2].

Core Viewpoint - The clinical data for HLX43, a PD-L1 ADC developed by the company, shows significant efficacy and safety in treating recurrent/metastatic cervical cancer, indicating strong commercial potential in the oncology market [1][2]. Efficacy and Safety - The Phase II clinical study included 30 patients with recurrent/advanced cervical cancer, all of whom had previously failed or were intolerant to standard first-line treatments [1]. - The overall objective response rate (ORR) was 41.4%, with a disease control rate (DCR) of 82.8%. The 3 mg/kg dosage group showed an ORR of 70.0% and a DCR of 100% [2]. - Safety data revealed that 60.0% of patients reported grade 3 or higher treatment-related adverse events (TRAEs), but there were no TRAEs leading to treatment discontinuation or death [2]. - Immune-related adverse events (irAEs) were reported in 23.3% of patients, primarily including thyroid dysfunction and skin rashes, with no grade 3 or higher irAEs, indicating manageable safety profiles [2]. Commercial Outlook - HLX43's efficacy data in cervical cancer is superior to other drugs in the same indication, with safety profiles comparable to competitors, suggesting a favorable commercial outlook [2]. - The company is conducting over 10 ongoing Phase Ib/II clinical trials for HLX43, with promising data already reported for non-small cell lung cancer and thymic cancer, and plans to expand indications to colorectal cancer, nasopharyngeal cancer, gastric cancer, and esophageal cancer [2]. Financial Forecast - The company projects total revenue of 5.873 billion, 5.912 billion, and 7.504 billion yuan for 2025-2027, reflecting year-on-year growth of 2.60%, 0.66%, and 26.92% respectively [3]. - Net profit attributable to shareholders is expected to be 827 million, 778 million, and 1.243 billion yuan for the same period [3].

Core Viewpoint - Zhongyin International reports that CSPC Pharmaceutical Group (01093) experienced a 6% quarter-on-quarter revenue growth in Q3 2025, reaching 6.6 billion RMB, primarily due to the absorption of negative impacts on traditional oncology products. However, net profit decreased by 10% to 964 million RMB due to a significant increase in operating expenses. The target price is adjusted to HKD 8.5, maintaining a "Hold" rating, which corresponds to a 20x P/E ratio for 2026 [1]. Revenue and Profit Analysis - Q3 2025 revenue reached 6.6 billion RMB, reflecting a 6% quarter-on-quarter increase [1] - Net profit for Q3 2025 decreased by 10% to 964 million RMB, attributed to rising operating expenses [1] Management Guidance - Management maintains guidance for a mid-single-digit recovery in H2 2025 compared to H1 2025, despite uncertainties from the upcoming national centralized procurement renewal and strict control of medical insurance fund expenditures [1] - Anticipated product launches in H1 2026 include innovative products (e.g., Bai Zi II, KN026) and biosimilars (e.g., Omadubmab, Pertuzumab), although management remains cautious about the domestic market outlook for 2026 [1] Strategic Focus - To address domestic uncertainties, internationalization is emphasized as a key strategic priority [1] - R&D expenses are expected to increase by 15% to 20% year-on-year in 2026 [1] Revenue Forecast Adjustments - Zhongyin International maintains its 2025 revenue forecasts due to Q3 performance meeting expectations, but lowers revenue forecasts for 2026 and 2027 by 5.8% and 8.5%, respectively, due to uncertainties from national centralized procurement and potentially slower new product sales growth [1]

Core Insights - Zhongjin International reported that CSPC Pharmaceutical Group (01093) achieved a quarterly revenue growth of 6% to 6.6 billion RMB in Q3 2025, primarily due to the absorption of negative impacts on traditional oncology products [1] - However, net profit decreased by 10% to 964 million RMB, mainly due to a significant increase in operating expenses [1] - The target price has been adjusted down to 8.5 HKD, maintaining a "Hold" rating, which corresponds to a 20x P/E ratio for 2026 [1] Revenue and Profit Analysis - All core therapeutic areas experienced sales growth, indicating a positive trend in the company's product performance [1] - The management maintains guidance for a mid-single-digit recovery in performance for the second half of 2025 compared to the first half [1] - The anticipated uncertainty from the upcoming national centralized procurement renewal and strict control of medical insurance fund expenditures has led to a cautious outlook for the domestic market in 2026 [1] Strategic Focus and R&D - The management emphasized that internationalization is a key strategic focus to address domestic uncertainties [1] - R&D expenses are expected to increase by 15% to 20% year-on-year in 2026, reflecting the company's commitment to innovation [1] - Despite the expected launch of innovative products and biosimilars in the first half of 2026, the management remains cautious about the growth rate of new product sales [1] Forecast Adjustments - Zhongjin International has maintained its 2025 forecasts due to Q3 performance meeting expectations [1] - However, revenue forecasts for 2026 and 2027 have been reduced by 5.8% and 8.5%, respectively, due to uncertainties surrounding the first to eighth batches of national centralized procurement and potential slower-than-expected sales growth of new products [1]

Core Viewpoint - The report from Zhongyin International indicates that the revenue of CSPC Pharmaceutical Group increased by 6% quarter-on-quarter to 6.6 billion yuan, primarily due to the recovery from negative impacts on traditional oncology products, with sales growth across all core therapeutic areas [1] Financial Performance - Revenue for the third quarter reached 6.6 billion yuan, reflecting a 6% increase compared to the previous quarter [1] - Net profit decreased by 10% to 964 million yuan, attributed to a significant rise in operating expenses [1] Management Guidance - Management maintains guidance for a mid-single-digit recovery in performance for the second half of 2025 compared to the first half [1] - Despite the anticipated launch of innovative products and biosimilars in the first half of 2026, management expresses caution regarding the domestic market outlook due to uncertainties from upcoming national procurement renewals and strict control of medical insurance fund expenditures [1] Forecast Adjustments - The firm has kept its 2025 revenue forecast unchanged, but has lowered the revenue projections for 2026 and 2027 by 5.8% and 8.5% respectively, due to uncertainties surrounding the national procurement renewals and potentially slower-than-expected sales growth of new products [1] - The target price has been adjusted down to 8.5 HKD, while maintaining a "Hold" rating [1]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - The acquisition of Crown Bioscience International by the report's subject company,艾迪康, for a base consideration of $204 million (approximately 1.48 billion RMB), marks a strategic shift from clinical testing services to drug development, aligning with the trend of collaborative development in precision medicine [3][13] - The report emphasizes the importance of CROs possessing translational medicine capabilities to facilitate the rapid transition from preclinical biomarkers to clinical trials and diagnostic processes [3] Summary by Sections Industry Overview -艾迪康 announced the acquisition of Crown Bioscience International, a global CRO focused on oncology and immuno-oncology drug discovery and development, with the transaction expected to complete by mid-2026 [3] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as 恒瑞医药, 百济神州, and 中国生物制药, as well as companies with significant single-product potential like 一品红 and 三生制药 [5] - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as 东诚药业 and 远大医药, and suggests monitoring the CXO sector for stable growth in R&D investment [5] Market Performance - The pharmaceutical sector saw a 3.29% increase last week, ranking 4th among 28 industries, while the Hong Kong pharmaceutical sector rose by 6.80%, ranking 2nd among 11 industries [7][30] - The report notes that the valuation of the pharmaceutical sector is currently at 30.89 times (TTM), with a premium of 22.29% over the overall A-shares [23]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval for its self-developed injectable drug POHERDY®1 (HLX11), indicating a significant advancement in the treatment of HER2-positive metastatic breast cancer [1] Group 1: FDA Approval Details - The FDA approved the biologics license application (BLA) for POHERDY®1, which is an injectable solution for intravenous use [1] - The approved indications include treatment for adult patients with HER2-positive metastatic breast cancer who have not previously received anti-HER2 therapy or chemotherapy [1] - The drug is also indicated for use in combination with trastuzumab and chemotherapy for early-stage breast cancer as part of a comprehensive treatment plan [1] Group 2: Treatment Applications - POHERDY®1 is indicated for neoadjuvant treatment in adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer [1] - It is also approved for adjuvant treatment in adult patients with HER2-positive early breast cancer who are at high risk of recurrence [1]